What is the technical and clinical success rate of the LTD coil (lung volume reduction coil) procedure for patients with severe emphysema?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

LTD Coil Success Rates for Severe Emphysema

Lung volume reduction coils demonstrate modest technical success with improvements in 6-minute walk distance and quality of life, but clinical benefits are small, short-lived, and accompanied by significant complications—making them a treatment option that requires careful patient selection and realistic expectation-setting.

Technical Success

The technical feasibility of coil placement is generally high, with procedures successfully completed in the vast majority of cases. Studies report placement of approximately 10-12 coils per treated lobe 1, 2, 3. The procedure itself can be performed bronchoscopically under general anesthesia with acceptable completion rates.

Clinical Success Rates

Functional Improvements

According to GOLD guidelines, two multicenter trials examining nitinol coils showed:

  • Increases in 6-minute walk distance compared to usual care
  • Smaller improvements in FEV1
  • Modest improvements in quality of life (measured by SGRQ) 1

However, the guidelines emphasize that additional data are needed to define optimal patient populations and compare long-term durability versus side effects 1.

Specific Outcome Data from Research Studies

Short-term benefits (6-12 months):

  • Quality of life improvement: SGRQ decreased by 11-12 points 3
  • 6-minute walk distance: increased by 30-51 meters 3
  • FEV1: increased by 0.11 L 3
  • Residual volume: decreased by 0.65-0.71 L 3
  • Dyspnea scores showed significant improvement 2, 4

Critical limitation: A 2021 retrospective analysis found that benefits were short-lived, with only 15.4% of patients showing sustained FEV1 improvement and 14.3% showing sustained residual volume improvement after 6 months 5. This study concluded that coils achieved "small and short-lived benefits" and "failed to improve 4-year overall survival" 5.

Durability of Response

The evidence reveals a concerning pattern:

  • Initial improvements at 6 months often diminish
  • One study showed no significant changes in pulmonary function tests at 12 months, though exercise capacity and dyspnea perception improved 4
  • Another study found improvements sustained at 12 months in selected patients 2
  • The most pessimistic data suggests treatment "failed to improve 4-year overall survival" 5

Safety Profile and Complications

Common adverse events (within 30 days):

  • Hemoptysis: 40% 5
  • COPD exacerbations: 6.1% 3
  • Pneumonia: 5.2-5.5% 3
  • Pneumothorax: 3.4-3.5% 5, 3
  • Major complications: 6.9% 5

Important caveat: The Mayo Clinic review of GOLD 2018 guidelines explicitly states that "bronchoscopic lung volume reduction technique with valves and coils lacks evidence of substantial benefit and is not approved for use in the United States" as of 2018 6.

Patient Selection Considerations

Based on the evidence, coils may be considered for:

  • Patients with severe emphysema and hyperinflation
  • Both heterogeneous and homogeneous emphysema patterns (post-hoc analyses showed responses in both) 3
  • Patients with positive collateral ventilation (where valves cannot be used) 7
  • Those who are not candidates for lung volume reduction surgery

However, given the limited durability, high complication rates, and lack of mortality benefit, this intervention should be reserved for highly selected patients after thorough shared decision-making about realistic expectations 5.

Clinical Bottom Line

While technically feasible with success rates approaching 90-95% for coil placement, the clinical success is limited. Approximately 45% of patients achieve minimal clinically important difference in walking distance 4, but sustained improvements beyond 6-12 months are seen in only a minority. The 4-year survival was 63.8%, which did not differ significantly from predicted survival based on BODE indices 5.

The procedure carries a 40% risk of hemoptysis and 3-7% risk of major complications, making the risk-benefit ratio unfavorable for most patients with severe emphysema 5. Current evidence suggests coils are "not worthwhile the risk for most patients" 5, though they may provide temporary symptomatic relief in carefully selected individuals who understand the limitations.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.